Tags

Type your tag names separated by a space and hit enter

Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels.
J Am Acad Dermatol. 2019 Mar; 80(3):694-700.JA

Abstract

BACKGROUND

Promising results with platelet-rich plasma (PRP) in androgenetic alopecia that could be associated with platelet number and growth factor levels were described.

OBJECTIVE

Analyze the platelet countand growth factor levels in PRP and their correlation with hair growth parameters evaluated by using the TrichoScan (Tricholog GmbH, Freiburg, Germany).

METHODS

A total of 26 patients were randomized to receive 4 subcutaneous injections of PRP or saline. Hair growth, hair density, and percentage of anagen hairs were evaluated by using the TrichoScan method before injection, 15 days after the last injection, and again 3 months after the last injection. Growth factors (platelet-derived growth factor, epidermal growth factor, and vascular endothelial growth factor) were measured by the Luminex method (Millipore, Bedford, MA).

RESULTS

We demonstrated a significant increase in hair count (P = .0016), hair density (P = .012) and percentage of anagen hairs (P = .007) in the PRP group versus in the control group, without correlation with platelet counts or quantification of the growth factors in PRP.

LIMITATIONS

Other growth factors that could be related to response to PRP were not evaluated.

CONCLUSION

Our data favor the use of PRP as a therapeutic alternative in the treatment of androgenetic alopecia. The lack of association between platelet count, platelet-derived growth factor, epidermal growth factor, and vascular endothelial growth factor levels and clinical improvement suggest that other mechanisms could be involved in this response.

Authors+Show Affiliations

Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil. Electronic address: brunnu.lima@gmail.com.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.Hemocentro, Hemostasis Laboratory, University of Campinas, Campinas, São Paulo, Brazil.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

30287324

Citation

Rodrigues, Bruno L., et al. "Treatment of Male Pattern Alopecia With Platelet-rich Plasma: a Double-blind Controlled Study With Analysis of Platelet Number and Growth Factor Levels." Journal of the American Academy of Dermatology, vol. 80, no. 3, 2019, pp. 694-700.
Rodrigues BL, Montalvão SAL, Cancela RBB, et al. Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels. J Am Acad Dermatol. 2019;80(3):694-700.
Rodrigues, B. L., Montalvão, S. A. L., Cancela, R. B. B., Silva, F. A. R., Urban, A., Huber, S. C., Júnior, J. L. R. C., Lana, J. F. S. D., & Annichinno-Bizzacchi, J. M. (2019). Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels. Journal of the American Academy of Dermatology, 80(3), 694-700. https://doi.org/10.1016/j.jaad.2018.09.033
Rodrigues BL, et al. Treatment of Male Pattern Alopecia With Platelet-rich Plasma: a Double-blind Controlled Study With Analysis of Platelet Number and Growth Factor Levels. J Am Acad Dermatol. 2019;80(3):694-700. PubMed PMID: 30287324.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels. AU - Rodrigues,Bruno L, AU - Montalvão,Silmara A L, AU - Cancela,Rebeca B B, AU - Silva,Francesca A R, AU - Urban,Aline, AU - Huber,Stephany C, AU - Júnior,José Luiz R C, AU - Lana,José Fábio S D, AU - Annichinno-Bizzacchi,Joyce M, Y1 - 2018/10/02/ PY - 2018/1/29/received PY - 2018/9/18/revised PY - 2018/9/20/accepted PY - 2018/10/6/pubmed PY - 2019/3/19/medline PY - 2018/10/6/entrez KW - PRP KW - alopecia KW - hair loss KW - platelet-rich plasma SP - 694 EP - 700 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 80 IS - 3 N2 - BACKGROUND: Promising results with platelet-rich plasma (PRP) in androgenetic alopecia that could be associated with platelet number and growth factor levels were described. OBJECTIVE: Analyze the platelet countand growth factor levels in PRP and their correlation with hair growth parameters evaluated by using the TrichoScan (Tricholog GmbH, Freiburg, Germany). METHODS: A total of 26 patients were randomized to receive 4 subcutaneous injections of PRP or saline. Hair growth, hair density, and percentage of anagen hairs were evaluated by using the TrichoScan method before injection, 15 days after the last injection, and again 3 months after the last injection. Growth factors (platelet-derived growth factor, epidermal growth factor, and vascular endothelial growth factor) were measured by the Luminex method (Millipore, Bedford, MA). RESULTS: We demonstrated a significant increase in hair count (P = .0016), hair density (P = .012) and percentage of anagen hairs (P = .007) in the PRP group versus in the control group, without correlation with platelet counts or quantification of the growth factors in PRP. LIMITATIONS: Other growth factors that could be related to response to PRP were not evaluated. CONCLUSION: Our data favor the use of PRP as a therapeutic alternative in the treatment of androgenetic alopecia. The lack of association between platelet count, platelet-derived growth factor, epidermal growth factor, and vascular endothelial growth factor levels and clinical improvement suggest that other mechanisms could be involved in this response. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/30287324/ DB - PRIME DP - Unbound Medicine ER -